Financings in Brief: Abiomed
This article was originally published in The Gray Sheet
Executive Summary
Abiomed: Offers to pay $10,000 in cash for each of the 135 outstanding partnership units of the Abiomed Limited Partnership. Under a prior financing agreement, Abiomed was required to pay the Partnership a 5.5% royalty on revenues generated from its BVS-5000 and SupraCor temporary cardiac support systems. Abiomed has since reduced that obligation to 4.9% by taking a 10.9% stake in the Partnership. If accepted by members of the Partnership, Abiomed's purchase "will further reduce or potentially eliminate its net royalty obligations," the company says. To pay $3.1 mil. in royalty obligations incurred before April 1, 1995, Abiomed recently issued to the Partnership 451,427 shares of its common stock ("The Gray Sheet" May 8, p. 13)...
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.